Drug intelligence / Profile preview

HY-088

Development stage: Preclinical
Lead developer: Hyloris Pharmaceuticals
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

HY-088 is an ultrasmall superparamagnetic iron oxide nanoparticle (USPIO) injection being developed as a contrast agent for magnetic resonance imaging (MRI). The drug consists of iron oxide crystals coated with polyacrylic acid (PAA) on the surface, which serves to stabilize the nanoparticles and enhance their biocompatibility. Developed by Sichuan Huiyu Seacross Pharmaceutical (a subsidiary of Huiyu Pharmaceutical) in collaboration with InnoStar Bio-tech, HY-088 functions by shortening the T2 and T2* relaxation times of water protons in the surrounding tissue, thereby improving image contrast. Preclinical studies in rat models have characterized its pharmacokinetic profile and tissue distribution, supporting its potential use in diagnostic imaging applications.

Other names: HY088HY-088HY 088

Beyond the preview

Go deeper on HY-088.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HY-088.